Inhibition of Induced Chemoresistance by Cotreatment with (E)-5-(2-Bromovinyl)-2'-Deoxyuridine (RP101)

Rudolf Fahrig,2 Jörg-Christian Heinrich, Bernd Nickel, Falk Wilfert, Christina Leisser, Georg Krupitza, Christian Praha, Denise Sonntag, Beate Fiedler, Harry Scherthan, and Heinrich Ernst

RESprotect, Dresden, Germany D-01307 [R. F., J.-C. H., F. W., C. P., D. S.]; Baxter Oncology, Frankfurt am Main, Germany 60314 [B. N.]; Institute of Clinical Pathology, University of Vienna, Vienna, Austria 1097 [C. L., G. K.]; Medical School Hannover, Hannover, Germany 30625 [B. F.]; Max-Planck-Institute for Molecular Genetics, Berlin, Germany 14195 [H. S.]; and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany 30625 [H. E.]

ABSTRACT

Induced chemoresistance leads to the reduction of apoptotic responses. Although several drugs are in development that circumvent or decrease existing chemoresistance, none has the potential to prevent or reduce its induction. Here, we present data from a drug that could perhaps fill this gap. Cotreatment of chemotherapy with (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU, RP101) prevented the decrease of apoptotic effects during the course of chemotherapcy and reduced nonspecific toxicity. Amplification of chemoresistance genes (Mdr1 and Dhfr) and overexpression of gene products involved in proliferation (DDX1) or DNA repair (UBE2N and APEX) were inhibited, whereas activity of NAD(P)H:quinone oxidoreductase 1 (NQO1) was enhanced. During recovery, when treatment was with BVDU only, microfilamental proteins were up-regulated, and proteins involved in ATP generation or cell survival (STAT3 and JUN-D) were down-regulated. That way, in three different rat tumor models, the antitumor efficiency of chemotherapy was optimized, and toxic side effects were reduced. Because of these beneficial properties of BVDU, a clinical pilot Phase I/II study with five human tumor entities has been started at the University of Dresden (Dresden, Germany). So far, no unwanted side effects have been observed.

INTRODUCTION

Repeated chemotherapeutic treatment frequently induces, or selects for, chemoresistance of remaining cancer cells by altering gene expression and inducing genomic instability because of mutation, recombination, and gene amplification events. Deregulation of DNA-repair enzymes is partly involved in this phenomenon (e.g. p53 gene, BRCA1/2, UBE2N, APEX, and Rad51). Furthermore, enzymes that metabolize and bioactivate drugs [e.g. dihydrofolate reductase (DHFR) (1) and NQO1 (2)] or proteins that transport cytotoxic agents (e.g. multidrug resistance protein (MDR1, Ref. 3)] often contribute to chemoresistance.

During the implementation of a long-term screening program for inhibitors of chemoresistance, BVDU(1) was the only substance of chemoresistance. Although several drugs are in development that circumvent or decrease chemoresistance, none has the potential to prevent or reduce its induction. Here, we present data from a drug that could perhaps fill this gap. Cotreatment of chemotherapy with (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU, RP101) prevented the decrease of apoptotic effects during the course of chemotherapy and reduced nonspecific toxicity. Amplification of chemoresistance genes (Mdr1 and Dhfr) and overexpression of gene products involved in proliferation (DDX1) or DNA repair (UBE2N and APEX) were inhibited, whereas activity of NAD(P)H:quinone oxidoreductase 1 (NQO1) was enhanced. During recovery, when treatment was with BVDU only, microfilamental proteins were up-regulated, and proteins involved in ATP generation or cell survival (STAT3 and JUN-D) were down-regulated. That way, in three different rat tumor models, the antitumor efficiency of chemotherapy was optimized, and toxic side effects were reduced. Because of these beneficial properties of BVDU, a clinical pilot Phase I/II study with five human tumor entities has been started at the University of Dresden (Dresden, Germany). So far, no unwanted side effects have been observed.

MATERIALS AND METHODS

Chemicals. DMBA, MMC, MTX, and DOX were from Sigma (Deisenhofen, Germany). MXA, cisplatin, glufosfamide, and DOX for in vivo tests were from Asta Medica (Frankfurt at Main, Germany). BVDU (RP101) was from RESprotect and Berlin-Chemie (Berlin, Germany). RNase was from Boehringer (Mannheim, Germany), and restriction enzymes were from New England Biolabs (Schwabach, Germany). All of the other chemicals were purchased from Sigma and Roth (Karlsruhe, Germany).

3T6 Cell Culture and Development of Methotrexate Resistance. Swiss albino mouse fibroblasts, 3T6, were grown in DMEM supplemented with 10% fetal bovine serum, penicillin, and streptomycin (Biochrom, Berlin, Germany). Cells (2.8 × 10⁶) were plated into 9 T25-flasks with MTX and 9 T25-flasks with MTX and 30 μM BVDU. As soon as cells approached confluency, they were trypsinized and replated at the next higher drug concentration. The MTX concentration was increased 1.5-fold at 1-week intervals for 60 days starting with 44 nm MTX. The number of living cells was determined using the Cell Counter and Analyser System CASY TT (Schärfe System GmbH, Reutlingen, Germany). Cell counting and cell volume determination were hereby based on the exploration of viable cell population. The signals generated by the cells suspended in an electrolyte were evaluated by pulse area analysis. The pulse area of the signal was strictly proportional to the volume of the particle generating the signal. In dead cells, the integrity of the cell membrane is lost. This loss increased the conductivity and reduced the pulse area of the electric signal. Thus, to exclude debris and dead cells, only particles with a size of >7.5 μm were counted as cells.

Treatment of AH13r Sarcoma Cells in Culture. AH13r cells, a subline of the rat Yoshida sarcoma, were obtained from the Cell and Tumor Bank of the West German Cancer Center, University Essen, Medical School (Essen, Germany). Cells were grown in DMEM (FG 0415; Biochrom AG, Berlin, Germany) supplemented with 10% (v/v) heat-inactivated fetal bovine serum, 100 units/ml penicillin, and 100 μg/ml streptomycin in a humidified atmosphere containing 5% CO₂ at 37 °C. Logarithmically growing cells were seeded at a density of 100,000 cells/ml and incubated with different cytostatic drugs in

Received 5/12/03; accepted 7/14/03.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported by the “Sächsische Aufbaubank” (Dresden/Germany) Project 6261, and the Fraunhofer-Society (München/Germany).

2 To whom requests for reprints should be addressed, at RESprotect, Fiedlerstr. 34, D-01307 Dresden, Germany. Phone: +493514503201; Fax: +493514503210; E-mail: fahrig@resprotect.de.

3 The abbreviations used are: BVDU, (E)-5-(2-bromovinyl)-2'-deoxyuridine; DOX, doxorubicin; MMC, mitomycin C; MXA, mitoxantrone; MALDI-MS, matrix-assisted laser desorption/ionization mass spectrometry; HOPI, Hoechst 33258/propidium iodide; DMBA, dimethylbenzanthrazene; CGH, comparative genome hybridization; ROS, reactive oxygen species.

[CANCER RESEARCH 63, 5745–5753, September 15, 2003]
combination with or without BVDU. After 2–4 days (unless otherwise indicated), cells were counted using the Cell Counter and Analyser System CASY TT (Schärfe System GmbH), and serially passaged.

**HOP1 Double Staining:** Apoptosis was assayed by HOP1 staining as described by Grusch et al. (10, 11). Viable, apoptotic, and necrotic cells were counted. The Hoechst 33258 dye stains the nuclei of all cells. Nuclear changes associated with apoptosis, such as chromatin condensation and nuclear fragmentation, can be readily monitored and quantified. Propidium iodide uptake indicates loss of membrane integrity characteristic for necrotic and late apoptotic cells. The selective uptake of the two dyes allows to distinguish between apoptotic and necrotic cell death. Necrosis is characterized in this system by nuclear propidium iodide uptake into cells without chromatin condensation or nuclear fragmentation.

**Treatment of AH13r Sarcomas in SD-Rats.** Ten SD-rats per treatment group were given a single s.c. injection of ascites Yoshida AH13r hepatoma cells. Five to 7 days after tumor application, the growth of the resulting tumors (at the injection site) was suppressed by i.p. treatment of the animals with 2 or 4 mg/kg DOX (9 times within 3 weeks), 120 or 140 mg/kg glosufamide (15 times within 3 weeks), and 0.5 or 1.5 mg/kg cisplatin only (4 or 5 times within 3 weeks), and by additional oral treatment with 15 mg/kg BVDU (15 times within 3 weeks).

**Treatment of DMBA-induced Fibrosarcomas and Mammary Adenocarcinomas in SD-Rats.** SD-rats (3.5 weeks old) were purchased from Harlan Winkelmann (Burchen, Germany). The care and use of the animals were in accordance with institutional guidelines.

At an age of 39 days, a total of 8 male and 8 female rats were administered s.c. 10 mg DMBA in 0.75 ml sesame oil (DAB 10) to induce fibrosarcomas at the injection site (neck) and (multiple) mammary adenocarcinomas in female rats. DMBA induces mammary tumors that are comparable with those in humans in terms of their long relative latency, histotypes, and endocrine responsiveness (12).

**Treatment with DOX or DOX + BVDU.** Beginning at an age of 128 days, 2 male and 2 female rats were administered three times a week for 8 weeks s.c. with 1 mg/kg DOX (0.9% NaCl solution). Another 3 male and 3 female rats were administered three times a week for 8 weeks s.c. with 1 mg/kg DOX and five times a week p.o. with 15 mg/kg BVDU (in corn oil). The control group of 3 male and 3 female rats received 1 ml of a 0.9% NaCl solution i.p., and 5 ml corn oil p.o. five times a week.

**Determining Tumor Incidences.** The rats were checked for tumors by palpation regularly twice a week. The rats were killed when the detectable tumor burden did not allow longer treatment. The surviving animals were killed 60 days after beginning the administration of DOX or DOX + BVDU. An autopsy was performed, and tumor samples were fixed in 10% formalin. All of the tumors were embedded in paraffin, sectioned at 4 μm, stained with H&E, and examined histologically. Another sample of each tumor was snap-frozen in liquid nitrogen and examined histologically. Another sample of each tumor was snap-frozen in liquid nitrogen and examined histologically. Another sample of each tumor was snap-frozen in liquid nitrogen and examined histologically.

**Southern Blot Analysis.** Analyses were performed using standard procedures (13).

**Western Blot Analysis.** Pelleted cells were suspended in buffer A (20 mM HEPES, 400 mM NaCl, 25% v/v glycerol, 1 mM EDTA, 0.5 mM NaF, 0.5 mM Na2VO4, and 0.5 mM DTT) according to Pagano et al. (14), supplemented with Complete Protease Inhibitor Tablets (Roche, Mannheim, Germany) as described by the manufacturer and then shock-frozen in liquid nitrogen, thawed on ice, and centrifuged (15 min, 4°C, 11,500 rpm). The concentration of protein in the supernatant was determined by the Bradford method using bovine γ-globulin as a standard (Bio-Rad, Munich, Germany).

**Two-Dimensional Gel Electrophoresis.** AH13r cells were treated for 17 days (36 h recovery for samples 5 and 6) as follows: (a) DMSO (untreated control); (b) BVDU; (c) MMC; (d) MMC + BVDU; (e) recovery after MMC treatment; and (f) recovery with BVDU after MMC + BVDU treatment. Proteins of each group were separated by two-dimensional gel electrophoresis. Differentially expressed proteins were identified by MALDI-MS.4

**RESULTS**

**In Vitro Experiments.** We first investigated 3T6 cells treated with increasing doses of MTX ± BVDU. 3T6 cells were chosen because of

---

4 Two-dimensional gel electrophoresis and MALDI-MS were performed by Proteome Factory (Berlin, Germany, http://www.proteomefactory.com).
their ability to amplify the \textit{Dhfr} gene forming double minutes during treatment with MTX (17). BVDU inhibited induction of \textit{Dhfr} amplification. Whereas treatment with MTX induced amplification of \textit{Dhfr} to give 4–27 copies (mean 14) after 39 days, cells cotreated with 10 \( \mu \text{g/ml} \) BVDU amplified the \textit{Dhfr} gene only 3–7 times (mean 4). Additional treatment sustained this effect (Fig. 1A).

Furthermore, BVDU cotreatment sensitized AH13r sarcoma cells for chemotherapy-induced apoptosis (Fig. 1B). BVDU cotreatment

![Fig. 1. In vitro experiments. A, \textit{Dhfr} gene amplification in mouse 3T6 cells (nine independent sublines each). B, effect of BVDU on cell numbers and apoptosis in AH13r rat sarcoma cells. Left, treatment with cytostatic drugs only, or in combination with BVDU (three independent experiments). DOX, 1.33 \( \mu \text{g/ml} \); MXA, day 0: 0.1 ng/ml, day 2: 0.1 ng/ml, day 5: 0.1 ng/ml, day 8: 0.15 ng/ml; MMC, day 0: 35 ng/ml, day 4: 50 ng/ml, day 8: 75 ng/ml, 10 \( \mu \text{g/ml} \) BVDU. Right, HOPI stain evaluation (mean value ± SD, nine independent experiments). C, effect of BVDU on the recovery of AH13r cells (three independent experiments).](https://cancerres.aacrjournals.org)
significantly reduced cell numbers. BVDU itself was nontoxic (data not shown). We detected increasing numbers of pyknotic cells (7.5–11.5 μm diameter) as a result of BVDU combinatorial treatment (Fig. 2A). This observation indicated an induction of apoptosis.

These results were confirmed by HOPI analysis (10; Fig. 2B). BVDU cotreatment increased the number of apoptotic cells on average by 15% (Fig. 1B, right).

We next investigated several survival pathways using Western blot analysis. This included the Akt/forkhead-related transcription factor pathway, the Raf/extracellular signal-regulated kinase, MDM2, p14, p53, p38, and survivin pathways. Neither of those appeared to be affected by BVDU cotreatment. Also, the expression patterns of several cell cycle regulators such as p27, p16, cyclin-dependent kinases, and cyclins remained unchanged (data not shown).

However, BVDU in combination, but not by itself, reduced the amount of the oncogene protein STAT3 to up to 50% (Fig. 3A).

Fig. 2. Assessment of apoptosis. A, treatment of AH13r rat sarcoma cells. Cell size distribution profiles obtained on day 14 of MMC treatment, using the CASY Cell Counter and Analyzer. AH13r cells were treated with 0.05% DMSO (control), 10 μg/ml BVDU, increasing doses of 35–75 ng/ml MMC only, and MMC+BVDU. B, apoptosis assay. HOPI staining image, example. Blue arrows, viable cells; yellow arrows, early apoptosis; white arrow, late apoptosis; red arrow, necrosis.

Moreover, in combination with DOX or MMC, this reduction of STAT3 expression by BVDU was maximal during recovery, when the cytostatic drug was omitted after previous treatment, but BVDU was still present (see Fig. 1C). Additionally, during MMC recovery, the oncogene protein JUN-D was overexpressed, but remained at control level in the presence of BVDU. Treatment was also accompanied by activation of caspase-3 (Fig. 3A).

We investigated NQO1 activity in cell extracts (16) after treatment with the cytostatic drugs ± BVDU (Fig. 3B). BVDU cotreated cells showed higher NQO1 activity than untreated control cells or cells treated with cytostatic drugs only. Interestingly, cells treated with MMC+BVDU, which caused the strongest antiproliferative effect, did not enhance NQO1 activity.

To elucidate the effects of BVDU, we performed a two-dimensional gel electrophoresis and identified differently expressed proteins by MALDI-MS (Table 1). During combinatorial MMC+BVDU treatment, or during recovery (MMC omitted, BVDU present) from combinatorial treatment, the expression of three major “clusters” of protein classes was affected: (a) microfilamental (or regulatory) proteins were up-regulated during recovery (actins, tubulin, myosin, and tropomodulin); (b) proteins involved in ATP generation were down-regulated (succinate dehydrogenase, pyruvate dehydrogenase, and malic enzyme; however, malate dehydrogenase was up-regulated); and (c) proteins regulating DNA repair were suppressed (APEX and UBE2N). One protein with oncogenic potential, DXI, was affected by BVDU alone. In total, ~75% of the spots were identified by MALDI-MS.

**In Vivo Experiments.** In vivo, BVDU enhanced anticarcinogenic effects on AH13r sarcomas in rats. Three cytostatic drugs of different mode of action (DOX, glufosfamide, and cisplatin) were tested in two independent experiments (Fig. 4A, panels 1 and 3). On the basis of previous results with rats (18), we used a daily dose of 15 mg/kg to gain peak plasma levels of ~25 µg/ml 20 min after application. After cotreatment, BVDU was additionally administered in the recovery phase for 4 days (Fig. 4).

The BVDU cotreated groups showed significantly less tumor growth. The tumor areas of these groups were significantly smaller than that of controls or the groups which were treated with cytostatic drugs only (Fig. 4A, panel 2), with the differences being significant at the 5% level (t-test/Mann-Whitney test).

Whereas the treatment with cytostatic drugs (DOX, cisplatin, and navelbine+ifosfamide+cisplatin) led to a defined loss of body weight, cotreatment with BVDU partly inhibited loss of body weight (Table 2). This may indicate reduced nonspecific toxicity and optimized antitumor efficiency of the BVDU cotreatment. If cytostatic treatment led to a gain of body weight, cotreatment with BVDU partly inhibited loss of body weight ifosfamide and navelbine (cisplatin) led to a defined loss of body weight, and BVDU was able to partly inhibit this loss of body weight. If cytostatic treatment led to a gain of body weight, cotreatment with BVDU partly inhibited loss of body weight ifosfamide and navelbine (cisplatin) led to a defined loss of body weight, and BVDU was able to partly inhibit this loss of body weight.

![Fig. 3. Effect of BVDU combinatorial treatment on protein expression. A. Western blot analysis, expression of STAT3, JUN-D, and caspase-3 (proteolytically activated form) in response to cytostatic drug treatment. The expression levels were determined densitometrically (r. = recovery, see Fig. 1C). B. NQO1 enzyme activity (mean value ± SD, six independent experiments).](image-url)

<table>
<thead>
<tr>
<th>Protein Description</th>
<th>Fold Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>BVDU only vs. control</td>
<td>control (1)</td>
</tr>
<tr>
<td>Deal/HBox 1, DDX1</td>
<td>~2.65</td>
</tr>
<tr>
<td>MMC + BVDU vs. MMC only</td>
<td>MMC only (1)</td>
</tr>
<tr>
<td>Protein disulfide isomerase/oxidoreductase, PDI</td>
<td>+2.56</td>
</tr>
<tr>
<td>Malate dehydrogenase, soluble, MDH1</td>
<td>+3.25</td>
</tr>
<tr>
<td>Myosin, heavy chain 1, neuronal similarity, adult, MYH1</td>
<td>+3.23</td>
</tr>
<tr>
<td>Ubiquitin-conjugating enzyme E2N; UBE2N</td>
<td>~3.76</td>
</tr>
<tr>
<td>Apurinic endonuclease, APE; APE1, APEX</td>
<td>~2.59</td>
</tr>
<tr>
<td>MMC + BVDU recovery, with BVDU</td>
<td>MMC recovery without BVDU (1)</td>
</tr>
<tr>
<td>Platelet-activating factor acetylhydrolase, isoform 1B, α subunit; PAFAH1B1</td>
<td>+2.83</td>
</tr>
<tr>
<td>U3 snRNP-specific protein, 116-KD</td>
<td>+2.62</td>
</tr>
<tr>
<td>Hemoglobin-β locus; HBB</td>
<td>+5.70</td>
</tr>
<tr>
<td>Hemoglobin-α locus 1; HBA1</td>
<td>+5.85</td>
</tr>
<tr>
<td>Actin, β; ACTB</td>
<td>+2.77</td>
</tr>
<tr>
<td>Similar to β-actin</td>
<td>+3.72</td>
</tr>
<tr>
<td>Actin-like</td>
<td>+3.55</td>
</tr>
<tr>
<td>Tropomodulin 2; TMOD2</td>
<td>+2.95</td>
</tr>
<tr>
<td>Succinate dehydrogenase complex, subunit A, SDHA</td>
<td>absent vs. 0.26</td>
</tr>
<tr>
<td>Pyruvate dehydrogenase complex, E1-α polypeptide 1, PDHA1</td>
<td>~3.29</td>
</tr>
<tr>
<td>Tubulin, β-5</td>
<td>~3.03</td>
</tr>
<tr>
<td>Poly(rC)-binding protein 2, PCBP2</td>
<td>~3.90</td>
</tr>
<tr>
<td>Malic enzyme 2; ME2</td>
<td>~3.02</td>
</tr>
<tr>
<td>Mini chromosome maintenance deficient 7; mitotin, cell division cycle-like 1; CDCL1</td>
<td>~3.14</td>
</tr>
</tbody>
</table>
In additional in vivo studies, BVDU cotreatment enforced growth retardation of DMBA-induced fibrosarcomas and mammary adenocarcinomas in SD-rats. The DMBA-induced fibrosarcoma growth of control animals surpassed the fibrosarcoma growth of the DOX-treated rats only at the end of the treatment period. In contrast, DOX+BVDU-treated animals showed an inhibited tumor growth over the whole time period analyzed (Fig. 3B, panel 1). When the areas of individual tumors were compared 53 days after treatment, the mean tumor area of the DOX+BVDU group was significantly smaller than that of the DOX or control group (Fig. 4B, panel 2).

DISCUSSION

Our results indicated that BVDU cotreatment enhanced chemosensitivity. This might have been because of: (a) inhibition of oncogenic and DNA repair-associated enzymes; (b) induction of NQO1 activity; (c) suppression of chemotherapy-induced Mdr1 or Dhfr gene amplification; or (d) inhibition of the overexpression of survival pathways and reduced expression of ATP-generating enzymes in the recovery phase.

Three rat tumor models gave evidence that BVDU cotreatment contributed significantly to tumor regression in vivo.

DDX1, which was down-regulated by BVDU alone, seems to be of special importance. DDX1 is coamplified with MYCN and overexpressed in a subset of neuroblastoma and retinoblastoma cell lines/tumors (20, 21). Preliminary studies have shown that neuroblastoma patients with amplification of both DDX1 and MYCN have a worse prognosis than patients with only the MYCN gene amplified (21). Thus, DDX1 seems to have oncogenic potential, and it is predicted to function by RNA binding and modulation of RNA secondary structure.

Of the five genes affected by BVDU cotreatment with MMC, two are linked to DNA repair. BVDU reduced the expression of UBE2N and APEX to ~30% of control level. The UBE2N gene encodes a ubiquitin-conjugating enzyme, which is thought to be involved in protein degradation. The protein complex containing UBE2N seems to be involved in the assembly of novel polyubiquitin chains for signaling in DNA repair and, through differential ubiquination of PCNA, affects resistance to DNA damage (22, 23).

Apurinic sites result from treatment with cytostatic drugs. The resulting abasic sites can block the progress of the DNA replication apparatus. These sites must be corrected to restore genetic integrity.

Table 2. BVDU reduced unspecific toxic effects in cytostatic drug-treated rats (mean of the data of six to seven rats)

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Change of mean area of AH13r rat sarcomas (day 1 = 1)</th>
<th>Day 14</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control (day 10)</td>
<td>20</td>
<td>+4%</td>
</tr>
<tr>
<td>9 × 4 mg/kg DOX only</td>
<td>4</td>
<td>-6%</td>
</tr>
<tr>
<td>DOX + 15 × 15 mg/kg BVDU</td>
<td>0.7</td>
<td>+4%</td>
</tr>
<tr>
<td>Control</td>
<td>25</td>
<td>+8%</td>
</tr>
<tr>
<td>Csplatin + 4 × 50 mg/kg BVDU</td>
<td>17</td>
<td>+2%</td>
</tr>
<tr>
<td>Control</td>
<td>15</td>
<td>+4%</td>
</tr>
<tr>
<td>4 × 5 mg/kg naveline + 4 × 50 mg/kg ifosfamide + 4 × 0.5 mg/kg cisplatin only</td>
<td>0.2</td>
<td>-5%</td>
</tr>
<tr>
<td>Naveline, ifosfamide and cisplatin + 4 × 50 mg/kg BVDU</td>
<td>0.2</td>
<td>+1%</td>
</tr>
</tbody>
</table>

Interestingly, in AH13r tumors or tumor cells, we could neither observe gene amplification or genome-wide changes (data not shown).3 We used in situ CGH (19) and PCR to test for amplification of genes that are frequently amplified in tumors, i.e. β-actin (control), ErbB2, Gsta1, Mdr1, c-Myc, n-Myc, and topoisomerase IIa/GST-1 encoding gene (Top2α).

In additional in vivo studies, BVDU cotreatment enforced growth retardation of DMBA-induced fibrosarcomas and mammary adenocarcinomas in SD-rats. The DMBA-induced fibrosarcoma growth of control animals surpassed the fibrosarcoma growth of the DOX-treated rats only at the end of the treatment period. In contrast, DOX+BVDU-treated animals showed an inhibited tumor growth over the whole time period analyzed (Fig. 3B, panel 1). When the areas of individual tumors were compared 53 days after treatment, the mean tumor area of the DOX+BVDU group was significantly smaller than that of the DOX or control group (Fig. 4B, panel 2).

We observed similar, but much more pronounced, effects with mammary adenocarcinomas (Fig. 4B, panel 1). DOX- (6 tumors) or DOX+BVDU-treated animals (9 tumors) showed an inhibited tumor growth over the whole treatment period in comparison with the control group (8 tumors). The areas of the individual tumors (Fig. 4B, panel 2) showed clear differences 39 days after treatment start. In 4 of 9 tumors of the DOX+BVDU group, a clear regression was observed. The overall tumor area of the DOX+BVDU group was significantly smaller than that of the DOX group or of controls. All of the differences were significant at the 5% level (t-test/Mann-Whitney test).

Tumors of rats treated with DOX showed amplification and/or overexpression of the Mdr1 gene, whereas tumors of DOX+BVDU-treated or control rats showed neither amplification nor overexpression (Fig. 4B, panel 3).

Fig. 4. SD-rats treated with DOX, glufosfamide, and cisplatin. A, rats with AH13r sarcomas. AI and A3, comparison of control animals, BVDU-control animals, cytostatic drug-treated animals, and cytostatic drug+BVDU-treated animals (calculation of the mean of all individual tumor areas). A2, tumor areas of 10–17 days after treatment start (—mean). B, rats with DMBA-induced fibrosarcomas and mammary adenocarcinomas. B1, top, SD-rats with DMBA-induced fibrosarcomas, calculation of the mean tumor area. Three control animals, three DOX-treated animals, and five DOX+BVDU-treated animals with fibrosarcomas. Bottom, DMBA-induced mammary adenocarcinomas, calculation of the mean of all individual tumor areas. Within the control animals, 8 tumors, within the DOX+BVDU-treated animals, 6 tumors, and within the DOX+BVDU-treated animals, 9 tumors could be observed. B2, area of the individual tumors 39 days after treatment start (—mean). B3, Mdr1 gene amplification and expression patterns of DMBA-induced fibrosarcomas and mammary adenocarcinomas in SD-rats. Representative tumor of 1) rat treated with solvent, 2) rat treated with DOX, and 3) rat treated with DOX+BVDU. Amplification of the Mdr1 gene was detected by Southern blot analysis and expression of the MDR1 protein by Western blot analysis using the murine anti-P-glycoprotein monoclonal antibody JSB-1. The densitometrically determined Mdr1 gene dosages (amplification levels) were subdivided into two categories: [square], indicate normal copy number; [clubs], amplification. [diamond] indicate that no analysis was performed because the whole tumor probe was used for histological analysis. Western blot analysis gave a yes [■] or no [□] result in respect to Mdr1 gene expression patterns. The numbers indicate different tumors examined (1 = male, 2 = female/animal number, position of mammary adenocarcinomas).
Silencing of APEX expression by RNA interference nearly doubled specific cell lysis, showing enhanced DNA nicking (24).

BVDU induced NQO1. This is in accordance with the observation that a multifactorial multidrug resistance phenotype of tumor cells involves a decrease and not an increase in NQO1 expression (9). NQO1 enzyme activity was enhanced in response to BVDU combination treatment with DOX or MXA, respectively. Hence, it can be speculated that enforced NQO1-mediated bioactivation of DOX and MXA could increase the cytotoxic potential of these drugs. On the other hand, MMC, its effects being strongest depending on NQO1 enzyme activity, showed no enhancement of NQO1 activity. Therefore, the sensitizing effect of BVDU does not seem to be implicitly NQO1-dependent.

Many of the drugs used in anticancer therapy, such as DOX and MXA (25), perturb the redox state and the mitochondrial respiration of the target cancer cell, which leads to the production of ROS. However, a subsequent burst of ROS will indiscriminately affect not only tumor cells but also normal tissue, which causes unwanted systemic side effects during therapy. NQO1 is a scavenger of ROS, and that way, induced NQO1 activity can protect cells from nonspecific ROS and electrophile attack (26). This may explain the improved therapeutic outcome against experimental tumors in vivo with no systemic toxicity and gain of body weight in response to BVDU cotreatment, as was observed in our animal models.

The first direct evidence that in some tumor cells overexpression of genes because of amplification gives cells a selective advantage in the presence of a cytostatic drug derives from analysis of tumor cells taken from patients treated with MTX, an inhibitor of the enzyme DHFR (1). Resistance to MTX in human tumors has in many cases been shown to be associated with amplification of the gene encoding DHFR (27). Furthermore, expression of the DHFR gene has been implicated in resistance to a variety of chemotherapeutic agents and has been detected in human ovarian and colon tumors (28).

In our experiments, treatment with DOX for 50 days caused Mdr1 gene amplification and overexpression in DMBA-induced rat tumors. Cotreatment with BVDU inhibited this cytostatic drug-induced effect. Beyond that, Dhfr gene amplification was inhibited in 3T6 mouse cells.

A comprehensive effect of BVDU was observed in the recovery phase. Gene products linked to survival, microfilament formation, differentiation, signal transduction, and ATP generation were affected. BVDU inhibited survival pathways and enforced apoptotic response. Therefore, it was demonstrated that dominant-negative JUN-D may activate the nuclear factor κB survival pathway. Moreover, p202, which is directly regulated by JUN-D, renders fibroblasts more refractory to apoptosis (31). In support of this reasoning, we demonstrated that BVDU cotreatment down-regulated the STAT3 and JUN-D survival pathways, thereby limiting chemoresistance.

ACKNOWLEDGMENTS

We thank Clemens Dasenbrock (Hannover, Germany) for supervising the in vivo experiments and Volkmer Rheese (Hannover, Germany) for performing them. Furthermore, we thank Christian Scheler, Proteome Factory (Berlin, Germany) for performance of the two dimensional gel-electrophoresis and protein identification by MALDI-MS.

REFERENCES


Inhibition of Induced Chemoresistance by Cotreatment with (E)-5-(2-Bromovinyl)-2′-Deoxyuridine (RP101)
